JP2022550459A5 - - Google Patents

Info

Publication number
JP2022550459A5
JP2022550459A5 JP2022520473A JP2022520473A JP2022550459A5 JP 2022550459 A5 JP2022550459 A5 JP 2022550459A5 JP 2022520473 A JP2022520473 A JP 2022520473A JP 2022520473 A JP2022520473 A JP 2022520473A JP 2022550459 A5 JP2022550459 A5 JP 2022550459A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methyl
octahydrocyclopenta
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520473A
Other languages
English (en)
Japanese (ja)
Other versions
JP7572734B2 (ja
JP2022550459A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053942 external-priority patent/WO2021067696A1/en
Publication of JP2022550459A publication Critical patent/JP2022550459A/ja
Publication of JP2022550459A5 publication Critical patent/JP2022550459A5/ja
Application granted granted Critical
Publication of JP7572734B2 publication Critical patent/JP7572734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520473A 2019-10-04 2020-10-02 ムスカリン性アセチルコリン受容体m4のアンタゴニスト Active JP7572734B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910863P 2019-10-04 2019-10-04
US62/910,863 2019-10-04
PCT/US2020/053942 WO2021067696A1 (en) 2019-10-04 2020-10-02 Antagonists of the muscarinic acetylcholine receptor m4

Publications (3)

Publication Number Publication Date
JP2022550459A JP2022550459A (ja) 2022-12-01
JP2022550459A5 true JP2022550459A5 (enExample) 2023-10-11
JP7572734B2 JP7572734B2 (ja) 2024-10-24

Family

ID=75337550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520473A Active JP7572734B2 (ja) 2019-10-04 2020-10-02 ムスカリン性アセチルコリン受容体m4のアンタゴニスト

Country Status (7)

Country Link
US (1) US12319701B2 (enExample)
EP (1) EP4037677B1 (enExample)
JP (1) JP7572734B2 (enExample)
AU (1) AU2020358000A1 (enExample)
CA (1) CA3155864A1 (enExample)
ES (1) ES3057371T3 (enExample)
WO (1) WO2021067696A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
US20230183218A1 (en) * 2020-04-24 2023-06-15 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20240174655A1 (en) * 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022261427A1 (en) * 2021-06-11 2022-12-15 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪(pyridazine)化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2011149995A1 (en) 2010-05-25 2011-12-01 Abbott Laboratories Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers
US20160200733A1 (en) * 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3416639B1 (en) 2016-02-16 2022-06-08 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
SMT202000554T1 (it) * 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
AU2018300980A1 (en) * 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019089676A1 (en) * 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
IL276411B2 (en) 2018-02-02 2024-04-01 Univ Vanderbilt M4 muscarinic acetylcholine receptor antagonists
AU2020402978A1 (en) 2019-12-10 2022-06-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2021119254A1 (en) 2019-12-10 2021-06-17 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230183218A1 (en) 2020-04-24 2023-06-15 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4139303A1 (en) 2020-04-24 2023-03-01 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
CA3199786A1 (en) 2020-11-18 2022-05-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP4491228A3 (en) 2020-12-22 2025-04-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN116669737A (zh) 2020-12-22 2023-08-29 范德堡大学 毒蕈碱型乙酰胆碱受体m4的拮抗剂
US20240174655A1 (en) 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022216655A1 (en) 2021-04-05 2022-10-13 Vanderbilt University N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
WO2022261427A1 (en) 2021-06-11 2022-12-15 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders

Similar Documents

Publication Publication Date Title
JP2022550459A5 (enExample)
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
AU2002346300B2 (en) Diamine derivatives
JP5352458B2 (ja) ヒスタミンh4受容体のベンゾフロ−およびベンゾチエノピリミジン系モジュレーター
ES2380395T3 (es) Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas
US9102686B2 (en) 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators
JP6936224B2 (ja) オクタヒドロピロロ[3,4−c]ピロール誘導体およびその使用
JP2015514073A5 (enExample)
AU2015335783B2 (en) Tricyclic atropisomer compounds
JP2014528433A5 (enExample)
JP2021534108A5 (enExample)
AU2003292828A1 (en) Diamine derivatives
JP2024542610A5 (enExample)
JP2006515844A5 (enExample)
IL225694A (en) History of methanesulfonylamino-phenyl, fluoro-phenyl or bicyclo (1.2.2)
MX2011006428A (es) Triazolopiridinas como inhibidores de fosfodiesterasa para tratamiento de enfermedades dermicas.
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
AU2014302550A1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
US20150290190A1 (en) [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS
JP2024543973A5 (enExample)
KR20230018387A (ko) Il-17의 조절제로서의 이미다조피리미딘
JP2022549601A5 (enExample)
JP2005515976A5 (enExample)
JP2023552838A5 (enExample)
JP2008508365A5 (enExample)